Avai Bio annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
2026
Avai Bio Shareholders’ Equity Growth & History (AVAI)
Avai Bio's shareholders’ equity was −$2.8M for fiscal 2026.
View full Avai Bio company overviewAvai Bio annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$2.8M | −$1.3M | — |
| 2025 | 2025-03-31 | −$1.6M | −$97,306 | — |
| 2024 | 2024-03-31 | −$1.5M | −$833,307 | — |
| 2023 | 2023-03-31 | −$633,259 | −$227,698 | — |
| 2022 | 2022-03-31 | −$405,561 | −$78,148 | — |
| 2021 | 2021-03-31 | −$327,413 | −$289,727 | — |
| 2020 | 2020-03-31 | −$37,686 | $11,926 | — |
| 2019 | 2019-03-31 | −$49,612 | — | — |
Avai Bio quarterly shareholders’ equity
As of Mar 31, 2018
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$3.2M | −$1.2M | — |
| Q4 2026 | 2026-03-31 | −$2.8M | −$1.3M | — |
| Q3 2026 | 2025-12-31 | −$2.8M | −$658,886 | — |
| Q2 2026 | 2025-09-30 | −$2.3M | −$485,293 | — |
| Q1 2026 | 2025-06-30 | −$2.0M | $93,198 | — |
| Q4 2025 | 2025-03-31 | −$1.6M | −$97,306 | — |
| Q3 2025 | 2024-12-31 | −$2.1M | −$734,716 | — |
| Q2 2025 | 2024-09-30 | −$1.8M | −$824,164 | — |
| Q1 2025 | 2024-06-30 | −$2.1M | −$1.1M | — |
| Q4 2024 | 2024-03-31 | −$1.5M | −$833,307 | — |
| Q3 2024 | 2023-12-31 | −$1.4M | −$861,402 | — |
| Q2 2024 | 2023-09-30 | −$991,302 | −$571,477 | — |
| Q1 2024 | 2023-06-30 | −$993,781 | −$553,764 | — |
| Q4 2023 | 2023-03-31 | −$633,259 | −$227,698 | — |
| Q3 2023 | 2022-12-31 | −$539,482 | −$122,542 | — |
| Q2 2023 | 2022-09-30 | −$419,825 | −$353,803 | — |
| Q1 2023 | 2022-06-30 | −$440,017 | −$507,278 | — |
| Q4 2022 | 2022-03-31 | −$405,561 | −$78,148 | — |
| Q3 2022 | 2021-12-31 | −$416,940 | −$82,816 | — |
| Q2 2022 | 2021-09-30 | −$66,022 | −$139,249 | — |
| Q1 2022 | 2021-06-30 | $67,261 | $53,870 | +402.29% |
| Q4 2021 | 2021-03-31 | −$327,413 | −$289,727 | — |
| Q3 2021 | 2020-12-31 | −$334,124 | −$201,468 | — |
| Q2 2021 | 2020-09-30 | $73,227 | $195,718 | — |
| Q1 2021 | 2020-06-30 | $13,391 | $104,889 | — |
| Q4 2020 | 2020-03-31 | −$37,686 | $11,926 | — |
| Q3 2020 | 2019-12-31 | −$132,656 | −$111,888 | — |
| Q2 2020 | 2019-09-30 | −$122,491 | −$120,731 | — |
| Q1 2020 | 2019-06-30 | −$91,498 | −$88,561.24 | — |
| Q4 2019 | 2019-03-31 | −$49,612 | −$52,873 | — |
| Q3 2019 | 2018-12-31 | −$20,768 | — | — |
| Q2 2019 | 2018-09-30 | −$1,760 | — | — |
| Q1 2019 | 2018-06-30 | −$2,936.76 | — | — |
| As of Mar 31, 2018 | 2018-03-31 | $3,261 | — | — |
Avai Bio shareholders’ equity trends
Over the last five fiscal years, Avai Bio's shareholders’ equity decreased from −$327,413 to −$2.8M, a change of −$2.5M. The latest reported quarter, Q1 2027, shows −$3.2M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Avai Bio source filings ↗